ADMA Biologics Inc (ADMA)
17.40
-0.50
(-2.79%)
USD |
NASDAQ |
Dec 20, 16:00
17.47
+0.07
(+0.40%)
After-Hours: 20:00
ADMA Biologics Net Income (Quarterly): 35.91M for Sept. 30, 2024
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 47.21M |
| Alnylam Pharmaceuticals Inc | -111.57M |
| Catalyst Pharmaceuticals Inc | 43.88M |
| Sarepta Therapeutics Inc | 33.61M |
| Krystal Biotech Inc | 27.18M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 119.84M |
| Total Expenses (Quarterly) | 80.20M |
| EPS Diluted (Quarterly) | 0.15 |
| Enterprise Value | 4.128B |
| Gross Profit Margin (Quarterly) | 49.78% |
| Profit Margin (Quarterly) | 29.96% |
| Earnings Yield | 1.61% |
| Operating Earnings Yield | 2.78% |
| Normalized Earnings Yield | 1.609 |